Table 2. Differential expression of serum proteins by both treatment groups (prednisone and infliximab), indicating the direction of change, and a description of the general protein function.

		Glucocorticoid cohort			Infliximab cohort
Gene	↑ or ↓	P-value	Pre (RFU)a	Post (RFU)a	P-value	Pre (RFU)a	Post (RFU)a	Description
SERPINA1	↓	<0.001	6.90±0.26	6.52±0.17	0.017	6.77±0.15	6.65±0.07	Increased in inflammation
IGFBP2	↓	0.003	10.88±0.47	10.17±0.34	0.006	6.90±0.40	6.40±0.48	Increased in inflammation
IGFBP1	↓	0.006	8.34±0.65	7.01±0.82	0.025	7.92±0.86	6.92±0.87	Increased in inflammation
RETN	↓	0.025	8.49±0.53	8.13±0.43	0.004	8.31±0.45	8.06±0.36	Increases cytokines
CCL23	↓	0.030	8.23±0.31	7.97±0.21	0.020	7.93±0.37	7.66±0.37	Chemotactic for monocytes
P4HB	↑	<0.001	6.02±0.05	6.14±0.07	0.001	6.10±0.09	6.22±0.09	Integrin binding
CNDP1	↑	<0.001	9.02±0.35	9.61±0.40	0.005	8.26±0.44	8.55±0.50	Improved cancer prognosis
CDH3	↑	<0.001	9.76±0.20	10.01±0.17	0.044	10.34±0.16	10.47±0.15	Cell adhesion
CCL25	↑	0.006	7.53±0.51	7.92±0.68	0.005	7.86±0.55	8.21±0.57	Protective in colitis
SPOCK2	↑	0.011	6.48±0.29	6.81±0.16	0.018	6.71±0.24	6.84±0.19	ECM binding
ADGRE2	↑	0.021	5.90±0.25	6.15±0.32	0.036	6.62±0.23	6.79±0.16	Promotes cytokine release
CHRDL1	↑	0.021	7.69±0.14	7.81±0.12	0.010	7.84±0.16	7.98±0.14	BMP4 antagonist
IFNA2	↑	0.024	5.27±0.12	5.33±0.09	0.023	4.98±0.09	5.04±0.10	JAK/STAT signaling
NCAM1	↑	0.026	8.89±0.31	9.11±0.21	0.030	9.10±0.23	9.26±0.20	Cell adhesion
AGT	↑	0.033	8.67±0.21	8.84±0.20	0.022	8.86±0.14	8.98±0.20	Vasoconstriction
IgM	↑	0.034	7.45±0.39	7.64±0.50	0.036	7.94±0.28	8.10±0.16	B-cell antibody
CNTF	↑	0.042	6.47±0.13	6.53±0.12	0.004	5.73±0.08	5.79±0.11	Protective in inflammation
CD36	↑	0.046	8.05±0.33	8.33±0.44	0.039	8.76±0.32	8.96±0.28	Pro-resolution M2

BMP4, bone morphogenetic protein 4; ECM, extracellular matrix; JAK/STAT, Janus kinase and a Signal Transducer and Activator of Transcription; M2, M2 macrophage; RFU, relative fluorescent units.

^aValues are log transformed mean±s.d.